Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | renal cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | renal cell carcinoma | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial (HCRN GU16-260), Opdivo (nivolumab) treatment in patients with CD274 (PD-L1)-positive treatment-naive advanced clear cell renal cell carcinoma resulted in an objective response rate (ORR) 50% (8/16) in patients with CD274 (PD-L1) expression between 1% to 20% and an ORR of 75% (6/8), median progression-free survival (PFS) of 20.6 months, and 1-year PFS rate of 75% in patients with CD274 (PD-L1) expression of 20% or higher (PMID: 35442713; NCT03117309). | 35442713 |
PubMed Id | Reference Title | Details |
---|---|---|
(35442713) | Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). | Full reference... |